Cargando…
High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity
Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here, we isolated a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889499/ https://www.ncbi.nlm.nih.gov/pubmed/26898190 http://dx.doi.org/10.1038/leu.2016.35 |